We also found no significant difference in 5-year OS rate between infected and noninfected patients with colorectal cancer with MSI-H (P = 0.24), with MLH1 hypermethylation (P = 0.74), with BRAF mutations (P = 0.41) and with KRAS mutation (P = 0.9; Supplementary Fig. S3B–S3E). This evidence concerns the gene KRAS and colorectal cancer.